Cytiva Establishes 30,000 Sq Ft Bioprocessing Facility in Bengaluru.

Cytiva has established a 30,000 sq ft bioprocessing facility in Bengaluru, aimed at accelerating drug development for biopharma companies in India and across the Asia-Pacific region.

The new centre is designed to help companies shorten development timelines, reduce manufacturing risks, and scale up operations, aligning with India’s ambition to expand its bioeconomy to $300 billion by 2030.

Equipped with single-use bioreactor systems that can scale up to 200 litres, the facility is capable of producing toxicity batch material to support preclinical development stages. The infrastructure is expected to provide end-to-end support for early-phase biologics development and process optimisation.

Pierre-Alain Ruffieux, Chief Operating Officer of Cytiva, said India’s scientific capabilities play a critical role in the global biopharma landscape. “India’s scientific strength plays a vital role in global biopharma, and this facility reinforces that momentum. By expanding our capabilities here, we’re giving customers the infrastructure to move from idea to impact with greater speed, reliability, and excellence,” he said.